Gilead Sciences shares fell after results from a phase 3 trial showed its antiviral drug remdesivir helped some patients with moderate Covid-19.
- Gilead says late-stage remdesivir trial shows improvement in some coronavirus patients CNBC
- Gilead’s stock falls on remdesivir data in moderately ill patients MarketWatch
- Gilead’s remdesivir shows some benefit in patients with moderate Covid-19 STAT
- Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19 Business Wire
- Gilead says remdesivir helped moderate coronavirus patients improve Fox Business